BARCELONA —Insulin degludec(Tresiba, Novo Nordisk) didn't reduce overall hypoglycemic events compared withinsulin glargineU300 (Toujeo, Sanofi) in a head-to-head trial of the two second-generation basal insulins in more than 1600 patients withtype 2 diabetes. But degludec was associated with lower...
Concentrated insulin analogs have recently been approved and are available for clinical use in the management of diabetes mellitus. One new product is insu
Dynamic risk factors associated with non‐severe hypoglycemia in patients treated with insulin glargine or exenatide once weekly 与每日一次使用甘精胰岛素或者每周一次使用艾塞那肽治疗的患者出现非严重低血糖相关的动态危险因素[J] . Sanjoy K. Paul,David Maggs,Kerenaftali Klein,Jennie H. Best.J...
Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US. J Med Econ. 2012;15(Suppl 2):6–13.Samyshkin Y, Guillermin A-L, Best JH, et al. Long-term cost- utility analysis of exenatide once weekly versus ...
Dynamic risk factors associated with non‐severe hypoglycemia in patients treated with insulin glargine or exenatide once weekly 与每日一次使用甘精胰岛素或者每周一次使用艾塞那肽治疗的患者出现非严重低血糖相关的动态危险因素[J] . Sanjoy K. Paul,David Maggs,Kerenaftali Klein,Jennie H. Best.Journal of ...
PDB14 USING HEALTH OUTCOMES MODELING TO ASSESS THE BENEFIT-RISK PROFILE OF EXENATIDE ONCE-WEEKLY VERSUS INSULIN GLARGINE FOR PATIENTS WITH TYPE-2 DIABETESObjectives Understanding the benefit-risk profiles of medications for type 2 diabetes (T2D) is of high public health interest. We assessed the ...